Source: PaxForex Premium Analytics Portal, Fundamental Insight Microsoft's stock price reached an all-time high after the tech behemoth published its first-quarter earnings report last Tuesday. The company's revenue increased 22% year-over-year to $45.3 billion, beating analysts' forecasts by $1.3 billion. Adjusted earnings surged 25% to $2.27 per share, $0.19 above expectations. For the second quarter, Microsoft management expects revenue growth of 16% to 18% year-over-year, which also beat analysts' expectations of 14%....
Source: PaxForex Premium Analytics Portal, Fundamental Insight UK Nationwide House Prices for October are predicted to increase 0.4% monthly and 9.3% annualized. Forex traders can compare this to UK Nationwide House Prices for September, which increased 0.1% monthly and 10.0% annualized. UK Mortgage Approvals for September are predicted at 70.95K. Forex traders can compare this to UK Mortgage Approvals for August, which were reported at 74.45K. UK Net Consumer Credit for September is predicted at £0.450B, and Net Mortgage Lending is...
Source: PaxForex Premium Analytics Portal, Fundamental Insight The reporting period always attracts the attention of investors and can guide a company's stock to meaningful changes. Now that the season is here, many organizations find themselves either winning or losing. A temporary loser was Intel, whose stock fell on Friday following the release of its Q3 results on Oct. 21. Investors sold their shares as the company failed to meet forecasts in several directions. Nevertheless, while Intel is having to overcome significant challenges...
Source: PaxForex Premium Analytics Portal, Fundamental Insight The Australian Import Price Index for the third quarter increased 5.4% quarterly, and the Australian Export Price Index increased 6.3% quarterly. Forex traders can compare this to the Australian Import Price Index for the second quarter, which increased 1.9% quarterly, and the Australian Export Price Index, which increased 13.2% quarterly. Foreign Buying of Japanese Bonds for the period ending October 23rd was reported at -¥604.5B, and Foreigners Buying of Japanese Stocks...
Source: PaxForex Premium Analytics Portal, Fundamental Insight Johnson & Johnson is a leader in several areas of pharmaceutical research, including oncology and immunologic diseases. The company's portfolio of drugs in these two areas brings in billions of dollars in revenue each quarter. The company is currently seeking to strengthen its market share in COVID-19 vaccines. This year, Johnson & Johnson anticipates generating $2.5 billion from sales of its COVID-19 vaccine, well below the $33.5 billion and $20 billion,...
